MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- SUVEN LIFE SCIENCES - TEVA PHARMA (Israel)
SUVEN LIFE SCIENCES vs TEVA PHARMA (Israel) - Comparison Results
TEVA PHARMA (Israel)
Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
Financials
 SUVEN LIFE SCIENCES  TEVA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUVEN LIFE SCIENCES Mar-19 |
TEVA PHARMA Dec-13 |
SUVEN LIFE SCIENCES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 338 | 3,043 | - | |
| Low | Rs | 169 | 2,643 | - | |
| Sales per share (Unadj.) | Rs | 52.1 | 1,746.3 | - | |
| Earnings per share (Unadj.) | Rs | 6.8 | 109.1 | - | |
| Cash flow per share (Unadj.) | Rs | 8.6 | 250.2 | - | |
| Dividends per share (Unadj.) | Rs | 1.50 | 95.50 | - | |
| Dividend yield (eoy) | % | 0.6 | 3.4 | 17.6% | |
| Book value per share (Unadj.) | Rs | 65.3 | 1,939.8 | - | |
| Shares outstanding (eoy) | m | 127.28 | 848.00 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.9 | 1.6 | 298.8% | |
| Avg P/E ratio | x | 37.1 | 26.1 | 142.4% | |
| P/CF ratio (eoy) | x | 29.6 | 11.4 | 260.4% | |
| Price / Book Value ratio | x | 3.9 | 1.5 | 265.0% | |
| Dividend payout | % | 22.0 | 87.5 | 25.1% | |
| Avg Mkt Cap | Rs m | 32,272 | 2,410,949 | 1.3% | |
| No. of employees | `000 | 1.1 | 44.9 | 2.4% | |
| Total wages/salary | Rs m | 661 | 0 | - | |
| Avg. sales/employee | Rs Th | 6,132.2 | 32,949.0 | 18.6% | |
| Avg. wages/employee | Rs Th | 611.1 | 0 | - | |
| Avg. net profit/employee | Rs Th | 803.5 | 2,058.3 | 39.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 6,635 | 1,480,891 | 0.4% | |
| Other income | Rs m | 242 | 0 | - | |
| Total revenues | Rs m | 6,877 | 1,480,891 | 0.5% | |
| Gross profit | Rs m | 1,604 | 405,543 | 0.4% | |
| Depreciation | Rs m | 221 | 119,702 | 0.2% | |
| Interest | Rs m | 38 | 29,087 | 0.1% | |
| Profit before tax | Rs m | 1,587 | 256,754 | 0.6% | |
| Minority Interest | Rs m | 0 | 1,166 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | -168,545 | 0.0% | |
| Tax | Rs m | 718 | -3,135 | -22.9% | |
| Profit after tax | Rs m | 869 | 92,510 | 0.9% | |
| Gross profit margin | % | 24.2 | 27.4 | 88.3% | |
| Effective tax rate | % | 45.2 | -1.2 | -3,704.7% | |
| Net profit margin | % | 13.1 | 6.2 | 209.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 6,232 | 1,000,188 | 0.6% | |
| Current liabilities | Rs m | 1,490 | 872,249 | 0.2% | |
| Net working cap to sales | % | 71.5 | 8.6 | 827.3% | |
| Current ratio | x | 4.2 | 1.1 | 364.7% | |
| Inventory Days | Days | 86 | 91 | 95.2% | |
| Debtors Days | Days | 83 | 96 | 86.1% | |
| Net fixed assets | Rs m | 4,043 | 483,692 | 0.8% | |
| Share capital | Rs m | 127 | 3,645 | 3.5% | |
| Net worth | Rs m | 8,310 | 1,644,989 | 0.5% | |
| Long term debt | Rs m | 18 | 757,212 | 0.0% | |
| Total assets | Rs m | 10,389 | 3,384,310 | 0.3% | |
| Interest coverage | x | 43.1 | 9.8 | 438.6% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.5% | |
| Sales to assets ratio | x | 0.6 | 0.4 | 146.0% | |
| Return on assets | % | 8.7 | 3.6 | 243.0% | |
| Return on equity | % | 10.5 | 5.6 | 186.0% | |
| Return on capital | % | 19.5 | 4.9 | 395.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 356 | 235,977 | 0.2% | |
| From Investments | Rs m | -279 | -83,616 | 0.3% | |
| From Financial Activity | Rs m | -225 | -283,071 | 0.1% | |
| Net Cashflow | Rs m | -148 | -130,710 | 0.1% | |
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.9 Rs / USD
Compare SUVEN LIFE SCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare SUVEN LIFE SCIENCES With: PANACEA BIOTECH J.B.CHEMICALS PROCTER & GAMBLE HEALTH NEULAND LABS STERLING BIOTECH
Today's Market
Wipro's Biggest Acquisition, Vodafone Idea Fundraising Plan, and Buzzing Stocks Today(Pre-Open)
Indian share markets witnessed huge selling during closing hours on Friday and ended lower.
Related Views On News
SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)
Jul 22, 2019 | Updated on Jul 22, 2019Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.
SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More
